Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Key Inclusion Criteria: * Signed and dated informed consent has been obtained prior to any protocol-related procedures. * Age ≥18 to \<75 years at the time of screening. * Diagnosed with chronic plaque psoriasis at least 6 months before randomisation. * Body weight ≥120 kg at the time of screening. * Moderate-to-severe plaque psoriasis as defined by: BSA ≥10% and PASI ≥12 at screening and baseline. * No evidence of active or latent tuberculosis according to local standard of care. Key Exclusion Criteria: * Diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g., eczema) that would interfere with evaluations of the effect of the investigational medicinal product (IMP) on participants with plaque psoriasis. * Clinically important active infections or infestations, chronic, recurrent or latent infections or infestations, or is immunocompromised (e.g., human immunodeficiency virus, hepatitis B, and hepatitis C). * Any systemic disease considered by the investigator to be uncontrolled and either immunocompromising the participants and/or placing the participant at undue risk of intercurrent diseases (including, but not limited to, renal failure, heart failure, liver disease, diabetes, and anaemia). * History of Crohn's disease. * Myocardial infarction or stroke, or unstable angina pectoris within the past 12 months. * Any active malignancy. * History of malignancy within 5 years, except for trea…